Failed Pediatric Drug Development Trials
Clinical Pharmacology & Therapeutics2015Vol. 98(3), pp. 245–251
Citations Over TimeTop 1% of 2015 papers
Abstract
Pediatric product development initiatives have stimulated the development of therapies for children, resulting in improved product labeling, increased identification of adverse events, and development of new pediatric formulations. However, 42% of recently completed pediatric trials have failed to establish either safety or efficacy, leading to an inability to label the product for use in children.(1) Characterizing these failed trials, including common contributing factors, is imperative to designing better pediatric trials in the future.
Related Papers
- → Do Current Clinical Trials Meet Society’s Needs?(2014)52 cited
- → Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006(2007)24 cited
- → Success rates for product development strategies in new drug development(2016)10 cited
- Phase 0 clinical trials will overcome stagnation of anticancer drug development?(2011)
- [Clinical trials in Norway--completion and reporting are not satisfactory].(2004)